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Abstract
Background: In a recent report, the carbohydrate-binding specificities of the plant lectins Galanthus nivalis (GNA)
and the closely related lectin from Zea mays (GNAmaize) were determined by glycan array analysis and indicated
that GNAmaize recognizes complex-type N-glycans whereas GNA has specificity towards high-mannose-type glycans.
Both lectins are tetrameric proteins sharing 64% sequence similarity.
Results: GNAmaize appeared to be ~20- to 100-fold less inhibitory than GNA against HIV infection, syncytia
formation between persistently HIV-1-infected HuT-78 cells and uninfected CD4+ T-lymphocyte SupT1 cells, HIV-1
capture by DC-SIGN and subsequent transmission of DC-SIGN-captured virions to uninfected CD4+ T-lymphocyte
cells. In contrast to GNA, which preferentially selects for virus strains with deleted high-mannose-type glycans on
gp120, prolonged exposure of HIV-1 to dose-escalating concentrations of GNAmaize selected for mutant virus strains
in which one complex-type glycan of gp120 was deleted. Surface Plasmon Resonance (SPR) analysis revealed that
GNA and GNAmaize interact with HIV IIIB gp120 with affinity constants (KD) of 0.33 nM and 34 nM, respectively.
Whereas immobilized GNA specifically binds mannose oligomers, GNAmaize selectively binds complex-type
GlcNAcb1,2Man oligomers. Also, epitope mapping experiments revealed that GNA and the mannose-specific mAb
2G12 can independently bind from GNAmaize to gp120, whereas GNAmaize cannot efficiently bind to gp120 that
contained prebound PHA-E (GlcNAcb1,2man specific) or SNA (NeuAca2,6X specific).
Conclusion: The markedly reduced anti-HIV activity of GNAmaize compared to GNA can be explained by the
profound shift in glycan recognition and the disappearance of carbohydrate-binding sites in GNAmaize that have
high affinity for mannose oligomers. These findings underscore the need for mannose oligomer recognition of
therapeutics to be endowed with anti-HIV activity and that mannose, but not complex-type glycan binding of
chemotherapeutics to gp120, may result in a pronounced neutralizing activity against the virus.
Background
Lectins represent a heterogeneous group of carbohy-
drate-binding proteins that are present in different spe-
cies (e.g. prokaryotes, plants, invertebrates and
vertebrates) and vary in size, structure and ability (affi-
nity for different glycan determinants) to bind carbohy-
drates. Plant lectins represent a large group of proteins
classified into twelve families, each typified by a particu-
lar carbohydrate binding motif [1]. At present, most stu-
dies have dealt with plant lectins classified as legume
lectins, chitin-binding lectins, type 2 ribosome inactivat-
ing proteins and monocot mannose-binding lectins
(MMBLs). After the identification of the first reported
MMBL from snowdrop bulbs, namely Galanthus nivalis
agglutinin (GNA) [2], lectins were isolated and charac-
terized from other closely related plant species. Similar
lectins were also identified outside plants, for example
in the fish Fugu rubripes [3] and in several
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Pseudomonas spp. [4,5]. GNA is the prototype of a
family of lectins that resemble each other with respect
to their amino acid sequences, three-dimensional struc-
tures, and sugar-binding specificities. The lectin subunits
of this class contain similar structural features, contain-
ing a b-barrel composed of 3 antiparallel four-stranded
b sheets [6].
Members of the GNA-related lectins have been inves-
tigated for their antiviral activity (in particular HIV).
Indeed, the plant lectins Galanthus nivalis agglutinin
(GNA) and Hippeastrum hybrid agglutinin (HHA) have
been described to inhibit viral entry [7,8], presumably by
their interaction with the glycans on HIV gp120. It has
been reported that these carbohydrate binding agents
(CBAs) block virus entry by inhibiting the fusion of cell-
free HIV particles with their target cells. Also, they pre-
vent the capture of virions by the DC-SIGN-receptor
present on dendritic cells of the innate immune system
and efficiently inhibit the subsequent transmission of
the virus to CD4+ T-cells. Besides blocking HIV entry,
CBAs have also the ability to select for virus strains in
which one or more glycans on gp120 are deleted. This
mechanism of drug escape results in the exposure of
previously hidden immunogenic epitopes on the virus
envelope glycoproteins [9].
Until recently, most plant lectin research was limited
to vacuolar plant lectins which have the advantage of
being present at relatively high quantities in seeds.
Nowadays, nucleocytoplasmic plant lectins can also be
efficiently isolated, even though they occur at low con-
centrations in the plant tissues. One example of a
nucleocytoplasmic plant lectin is the maize homolog of
the vacuolar GNA [10]. This GNA-like lectin from Zea
mays (GNAmaize) of which the gene was cloned and
expressed in Pichia pastoris by Fouquaert and co-work-
ers [10] shows 64% sequence similarity with GNA from
snowdrop.
All the reported GNA-related lectins including GNA-
maize have homologous sequences and structural simila-
rities. Despite this similarity at the protein level, this
class of lectins may display important differences in the
post-translational processing of the precursors [6]. Many
GNA-related lectins are indeed synthesized as prepro-
proteins and then converted in the mature polypeptide
by the co-translational cleavage of a signal peptide and
the post-translational removal of a C-terminal peptide
[10]. However, more recently it was shown that some
GNA-related lectins are synthesized without a signal
peptide and as a consequence are located in the nucleo-
cytoplasmic compartment of the plant cell. This proces-
sing results in a different subcellular localization of the
lectin. The GNA homolog from maize (GNAmaize) is
processed in such a way and is, therefore, in contrast to
the vacuolar GNA, located in the cytoplasm [10,11].
Native GNA is a tetrameric protein of 50 kDa with
three carbohydrate-binding motifs in each monomer
and was originally isolated from snowdrop bulbs [2].
GNA was originally described as a lectin with a specifi-
city towards Mana1,3Man-containing oligosaccharides
[12]. The molecular mass of the native recombinant
GNAmaize is 60 kDa and the lectin exists also as a tetra-
mer with 3 carbohydrate-binding sites per monomer
[11]. However, it was reported before that gene diver-
gence may have a serious impact on the carbohydrate-
binding potential of lectins [13]. Sequence alignments
revealed that only the third carbohydrate-binding site
(CBS) is similar between the GNAmaize and the GNA
lectin, whereas the first and second CBS differ with only
2 and 1 amino acid changes, respectively [11]. However,
glycan microarray analysis revealed striking differences
in glycan specificity. GNAmaize interacts preferentially
with complex-type glycans, whereas GNA almost exclu-
sively binds to high-mannose-type glycans [11]. Fou-
quaert and colleagues hypothesized that this difference
in glycan-binding properties reflects the ~100-fold
decreased anti-HIV-1 activity of GNAmaize when com-
pared to GNA [11].
To reveal in more detail the correlation between gene
divergency of GNA and GNAmaize, as well as the change
in carbohydrate-binding specificity and differences in
anti-HIV activity, we now report a detailed study of
GNAmaize (in comparison with GNA) covering its anti-
HIV activity, its kinetic interaction with the HIV-1
envelope glycoprotein gp120, epitope mapping experi-
ments to determine its glycan specificity on gp120 and
its antiviral resistance spectrum.
Methods
Test compounds
The mannose-specific plant lectin GNA from snowdrop
and the cytoplasmatic GNAmaize from maize were
derived and purified as described previously [2,11].
GlcNAcß1,2Man, (a1,3-man)2 and (b1,4-GlcNAc)3 were
obtained from Dextra Laboratories (Reading, UK).
(a1,2-man)3 was purchased from Carbohydrate Synth-
esis (Oxford, UK). The anti-gp120 2G12 mAb was
obtained from Polymun Scientific GmbH (Vienna, Aus-
tria). The lectins Phaseolus vulgaris Erythroagglutinin
(PHA-E) and Sambucus nigra agglutinin (SNA) from
elderberry were from Vector Laboratories (Peterbor-
ough, UK).
Cells
Human T-lymphocytic CEM, C8166, HuT-78 and Sup-
T1 cells were obtained from the American Type Culture
Collection (Manassas, VA, USA). The Raji/DC-SIGN
cells were constructed by Geijtenbeek et al. [14] and
kindly provided by L. Burleigh (Institut Pasteur, Paris,
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France). Persistently HIV-infected HuT-78/HIV cells
were obtained upon cultivation for 3 to 4 weeks of
HuT-78 cell cultures exposed to HIV-1(IIIB). All cell
lines were cultivated in RPMI-1640 medium (Invitrogen,
Merelbeke, Belgium) supplemented with 10% fetal
bovine serum (FBS) (BioWittaker Europe, Verviers, Bel-
gium), 2 mM L-glutamine, 75 mM NaHCO3 and 20 μg/
ml gentamicin (Invitrogen).
Viruses
HIV-1(IIIB) and HIV-1(BaL) were a kind gift from R.C.
Gallo (Institute of Human Virology, University of Mary-
land, Baltimore, MD) (at that time at the NIH, Bethesda,
MD) and HIV-2(ROD) was provided by L. Montagnier
(at that time at the Pasteur Institute, Paris, France). The
following clinical isolates were used: UG273 (clade A,
R5), DJ259 (clade C, R5) and ID12 (clade A/E, R5).
Antiretrovirus assays
CEM cells (5 × 105 cells per ml) were suspended in
fresh culture medium and infected with HIV-1 and
HIV-2 at 100 times the CCID50 (50% cell culture infec-
tive doses) per ml of cell suspension, of which 100 μl
was mixed with 100 μl of the appropriate dilutions of
the test compounds, and further incubated at 37°C.
After 4 to 5 days, syncytia formation was recorded
microscopically in the cell cultures. The 50% effective
concentration (EC50) corresponds to the compound con-
centration required to prevent syncytium formation by
50% in the virus-infected CEM cell cultures.
Buffy coat preparations from healthy donors were
obtained from the Blood Bank in Leuven. Peripheral
blood mononuclear cells (PBMC) were isolated by den-
sity gradient centrifugation over Lymphoprep (density =
1.077 g/ml; Nycomed, Oslo, Norway). The PBMC were
transferred to RPMI 1640 medium supplemented with
10% fetal calf serum (BioWhittaker Europe) and 2 mM
L-glutamine and then stimulated for 3 days with phyto-
hemagglutinin (PHA; Murex Biotech Limited, Dartford,
United Kingdom) at 2 μg/ml. HIV-infected or mock-
infected PHA-stimulated blasts were cultured in the pre-
sence of 10 ng of interleukin-2/ml and various concen-
trations of GNA and GNAmaize. Supernatant was
collected at days 8 to 10, and HIV-1 core antigen in the
culture supernatant was analyzed by the p24 core anti-
gen enzyme-linked immunosorbent assay (ELISA;
DuPont-Merck Pharmaceutical Co., Wilmington, Del.).
Co-cultivation assay between Sup-T1 and persistently
HIV-1-infected HuT-78 cells
Persistently HIV-1(IIIB)-infected HuT-78 cells (desig-
nated HuT-78/HIV-1) were washed to remove cell-free
virus from the culture medium, and 5 × 104 cells (50 μl)
were transferred to 96-well microtiter plates. Next, a
similar amount of Sup-T1 cells (50 μl) and appropriate
concentrations of test compound (100 μl), were added
to each well. After 1 to 2 days of co-culturing at 37°C,
the EC50 values were quantified based on the appear-
ance of giant cells by microscopical inspection.
Capture of HIV-1(IIIB) by Raji/DC-SIGN cells and
subsequent co-cultivation with C8166 cells
The experiment was performed as described previously
[15]. Briefly, B-lymphocyte DC-SIGN-expressing (Raji/
DC-SIGN) cells were suspended in cell culture medium
at 2 × 106 cells/ml. 100 μl of HIV-1(IIIB) (~250,000 pg
p24) were added in the presence of 400 μl of serial dilu-
tions of the test compounds. After 60 minutes of incu-
bation, the cells were carefully washed 3 times to
remove unbound virions and resuspended in 1 ml of
cell culture medium. The captured HIV-1(IIIB) was
quantified by a p24 Ag ELISA. From the Raji/DC-SIGN
cell suspension, 200 μl were also added to the wells of a
48-well microtiter plate in the presence of 800 μl unin-
fected C8166 cells (2.5 × 105 cells/ml). These cocultures
were further incubated at 37°C, and syncytia formation
was evaluated microscopically after ~ 18 to 42 h, and
viral p24 Ag determination in the culture supernatants
was performed.
Selection and isolation of GNAmaize-resistant HIV-1 strains
CEM cells were infected with HIV-1(IIIB) and seeded in
48-well plates in the presence of GNAmaize at a concen-
tration equal to one- to two-fold its EC50. Three inde-
pendent series of subcultivations were performed for
GNAmaize. The compound concentration was increased
stepwise (~ 1.5-fold) when full cytopathic effect was
detected. Subcultivations occurred after every 4 to 5
days by transferring 100 μl cell suspension of the GNA-
maize-exposed HIV-infected cells to 900 μl uninfected
CEM cell cultures.
Genotyping of the HIV-1 env region
Viral RNA was extracted from virus supernatants using
the QIAamp Viral RNA Mini Kit (Westburg, Heusden,
the Netherlands). The genotyping of both Env genes,
gp120 and gp41, were determined in this assay as
described previously [16].
Surface plasmon resonance (SPR) analysis
Recombinant gp120 proteins from HIV-1(IIIB) (Immu-
noDiagnostics Inc., Woburn, MA), one batch produced
by CHO cell cultures and another by insect cells (Bacu-
lovirus) were covalently immobilized on a CM5 sensor
chip in 10 mM sodium acetate, pH 4.0, using standard
amine coupling chemistry. The exact chip densities are
summarised in the results section. A reference flow cell
was used as a control for non-specific binding and
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refractive index changes. All interaction studies were
performed at 25°C on a Biacore T100 instrument (GE
Healthcare, Uppsala, Sweden). The plant lectins GNA
and GNAmaize were serially diluted in HBS-P (10 mM
HEPES, 150 mM NaCl and 0.05% surfactant P20; pH
7.4) supplemented with 0.2 mM Ca2+, covering a wide
concentration range by using two-fold dilution steps.
Samples (often in duplicate) were injected for 2 minutes
at a flow rate of 45 μl/min and the dissociation was fol-
lowed for 8 minutes. Several buffer blanks were used for
double referencing. The CM5 sensor chip surface was
regenerated with 1 injection of 50 mM NaOH and with
1 injection of Glycine-HCl pH 1.5 for GNAmaize and
GNA, respectively. All studied interactions resulted in
specific binding signals. The shape of the association
and dissociation phases reveals that the curves are not
following 1:1 Langmuir kinetics. The experimental data
were fit using the 1:1 binding model (Biacore T100 Eva-
luation software 2.0.2) to determine the binding kinetics.
These affinity and kinetic values are apparent values as
the injected concentrations of the evaluated compounds
did result in biphasic binding signals.
To generate more information on the glycan specifi-
city of GNAmaize and GNA, three different SPR-based
experiments were performed. In the first set-up, the sen-
sor chip was immobilized with GNA and GNAmaize and
binding with the (a1,2-man)3, (a1,3-man)2, (b1,4-
GlcNAc)3, and GlcNAcß1,2Man analytes was examined
as described above. The experimental data were fit using
the steady-state affinity model (Biacore T100 Evaluation
software 2.0.2) to determine the apparent KD-values. In
the second set-up, a competition assay of GNAmaize,
GNA and the anti-gp120 2G12 mAb for binding to
immobilized HIV-1 gp120 was performed in which one
of each of the compounds was administered for 2 min-
utes to immobilized gp120 and by the end of this time
period, the initial compound concentration was sus-
tained but now in the additional presence of one of the
two other compounds. In a third set-up, a competition
experiment for binding of GNA, GNAmaize and the mAb
2G12 to HIV-1 gp120 was performed with PHA-E (pre-
fers binding to GlcNAcß1,2man- and Galß1,4GlcNAc
determinants) and SNA (prefers binding to NeuAca2,6-
and to a lesser degree NeuAca2,3-X determinants).
Molecular modeling
Homology modeling of GNAmaize was performed on a
Silicon Graphics O2 10000 workstation, using the pro-
grams InsightII, Homology and Discover (Accelrys, San
Diego CA, USA). The atomic coordinates of GNA
complexed to mannose (code 1MSA) [17] were taken
from the RCSB Protein Data Bank [18] and used to
build the three-dimensional model of the GNA-like
lectin from maize. The amino acid sequence alignment
was performed with CLUSTAL-X [19] and the Hydro-
phobic Cluster Analysis (HCA) [20] plot was generated
http://mobyle.rpbs.univ-paris-diderot.fr/cgi-bin/portal.
py?form=HCA to recognize the structurally conserved
regions common to GNA and GNAmaize. Steric con-
flicts resulting from the replacement or the insertion
of some residues in the modeled lectin were corrected
during the model building procedure using the rota-
mer library [21] and the search algorithm implemented
in the Homology program [22] to maintain proper
side-chain orientation. Energy minimization and
relaxation of the loop regions were carried out by sev-
eral cycles of steepest descent using Discover3. After
correction of the geometry of the loops using the mini-
mize option of TurboFrodo, a final energy minimiza-
tion step was performed by 100 cycles of steepest
descent using Discover 3, keeping the amino acid resi-
dues forming the carbohydrate-binding sites con-
strained. The program TurboFrodo (Bio-Graphics,
Marseille, France) was used to draw the Ramachandran
plots [23] and perform the superimposition of the
models. PROCHECK [24] was used to check the
stereochemical quality of the three-dimensional model:
74.8% of the residues were assigned to the most
favourable regions of the Ramachandran plot (77.6%
for GNA). Cartoons were drawn with Chimera [25].
Molecular surface and electrostatic potentials were
calculated and displayed with GRASP using the parse3
parameters [26]. The solvent probe radius used for
molecular surfaces was 1.4 Å and a standard 2.0 Å-
Stern layer was used to exclude ions from the molecular
surface [27]. The inner and outer dielectric constants
applied to the protein and the solvent were fixed at 4.0
and 80.0, respectively, and calculations were performed
keeping a salt concentration of 0.145 M. Surface topol-
ogy of the carbohydrate-binding sites was rendered and
analyzed with PyMol (W.L. DeLano, http://pymol.org).
The docking of methyl mannose (MeMan) into the
carbohydrate-binding sites of GNAmaize was performed
with the program InsightII (Accelrys, San Diego CA,
USA). The lowest apparent binding energy (Ebind
expressed in kcal.mol-1) compatible with the hydrogen
bonds (considering Van de Waals interactions and
strong [2.5 Å < dist(D-A) < 3.1 Å and 120° < ang(D-H-
A)] and weak [2.5 Å < dist(D-A) < 3.5 Å and 105° < ang
(D-H-A) < 120°] hydrogen bonds; with D: donor, A:
acceptor and H: hydrogen) found in the GNA/Man
complex (RCSB PDB code 1MSA) [17] was calculated
using the forcefield of Discover3 and used to anchor the
pyranose ring of the sugars into the binding sites of the
lectin. The positions of mannose observed in the GNA/
Man complex were used as starting positions to anchor
mannose in the carbohydrate-binding sites of GNAmaize.
Cartoons showing the docking of MeMan in the
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mannose-binding sites of the lectins were drawn with
Chimera and PyMol.
Results
Antiviral activity of GNA and GNAmaize against HIV-1(IIIB)
and HIV-2(ROD) infection
GNA and GNAmaize inhibited the HIV-1- and HIV-2-
induced cytopathic effect in CEM cell cultures (Table 1
and Figure 1, Panels A and B). The EC50 (50% effective
concentration) values of GNA for HIV-1(IIIB) and HIV-
2(ROD) were 0.007 μM and 0.008 μM, respectively.
GNAmaize was found to be much less active against the
two virus strains with EC50-values of 0.46 μM and >0.83
μM, respectively. Thus, GNA is ~60 to ≥100-fold more
potent as an anti-HIV agent than GNAmaize. A similar
phenomenon is also observed for their activity against
several HIV-1 clade clinical isolates tested in PBMC
(Table 2).
Activity of CBAs on syncytia formation in co-cultures
between HuT-78/HIV-1 and Sup-T1 cells
GNAmaize could not efficiently prevent syncytia forma-
tion between persistently HIV-1(IIIB)-infected HuT-78/
HIV-1 cells and uninfected CD4+ T-lymphocyte SupT1
cells (EC50 >1.7 μM), whereas GNA was able to prevent
syncytia formation in the co-cultures at an EC50 of
0.062 μM (Table 1 and Figure 1, Panel C).
Effect of GNA and GNAmaize on the capture of HIV-1 by
Raji/DC-SIGN cells and on subsequent virus transmission
to uninfected CD4+ T-cells
We also investigated the potential of GNAmaize to pre-
vent HIV-1(IIIB) capture by DC-SIGN using Raji cells
transfected with DC-SIGN; and, next, the potential to
decrease the transmission of DC-SIGN-captured virions
to uninfected CD4+ T-lymphocyte C8166 cells. HIV-1
was shortly (30 minutes) exposed to different GNA and
GNAmaize concentrations before the virus was added to
the DC-SIGN-expressing Raji/DC-SIGN cells. One hour
later, free virus particles and the test compounds were
carefully removed from the cell cultures by several
washing steps. P24 Ag ELISA analysis revealed that
GNAmaize dose-dependently inhibited HIV-1(IIIB) cap-
ture by Raji/DC-SIGN cells with an EC50 of 0.90 μM. In
this assay, GNA was 20-fold more potent in inhibiting
virus capture than GNAmaize (Table 3 and Figure 1,
Panel D). Next, the washed GNAmaize/GNA-treated
HIV-1-exposed Raji/DC-SIGN cells were co-cultured
with CD4+ T-lymphocytes C8166 cells and syncytia for-
mation was recorded microscopically within 24 to 48
hours after co-cultivation. GNAmaize inhibited HIV-1
transmission at an EC50 of 0.44 μM which was 70-fold
less efficient than GNA (Table 3 and Figure 1, Panel E).
Selection of GNAmaize -resistant HIV-1(IIIB) strains and
determination of mutations in the gp160 gene of
GNAmaize-exposed HIV-1(IIIB) strains
HIV-1(IIIB)-infected CEM cell cultures were exposed to a
GNAmaize concentration comparable to its EC50. Three
independent series of GNAmaize selections were done
(Figure 2). Subcultivations were performed every 4 to 5
days. Virus-induced giant cell formation was recorded
microscopically, and the drug concentration was
increased 1.5-fold when full cytopathic effect was scored.
Virus isolates were taken (arrows in Figure 2) during the
selection process and analyzed for amino acid changes in
the viral envelope gene (encoding for gp120 and gp41).
Two different mutations were observed in putative N-
glycosylation motifs in gp120 and one mutation in gp41
when considering all virus isolates that were subjected to
genotypic analysis (Table 4). The virus isolates at pas-
sages GNAmaize_1#8, GNAmaize_1#19, GNAmaize_2#14,
GNAmaize_3#19 and GNAmaize_3#27 contained only one
N-glycosylation site deletion in gp120, being N/Y301Y.
The deleted N-glycan in gp120 found to occur in the
GNAmaize selection experiments (N301) was previously
determined as a complex-type glycan [28]. One new N-
glycosylation motif appeared at amino acid position 29 in
gp120 of virus isolate GNAmaize_3#16. In this virus isolate
a single N-glycosylation site deletion in gp41 was
observed at amino acid position 811NAT/I813.
Kinetic analysis of the interaction of GNA and GNAmaize
with HIV-1 IIIB gp120
The interaction of both plant lectins with HIV-1 gp120
was subjected to a detailed kinetic characterization by
surface plasmon resonance (SPR) analysis. GNAmaize and
GNA were evaluated against HIV-1(IIIB) gp120, derived
from either mammalian CHO cells and from insect cells
(Baculovirus system). Two-fold serial dilution series of
GNA and GNAmaize (covering a concentration range of
5 to 80 nM and 39 to 625 nM, respectively) were
applied to the gp120 immobilized on a CM5 sensor
chip. A 1:1 Langmuir kinetic fit was applied to obtain
the apparent kinetic association rate constant ka (kon,
on-rate) and dissociation rate constant kd (koff, off-rate)
Table 1 Anti-HIV activity of GNAmaize and GNA in
different cell systems
CBA HIV-1(IIIB)
EC50
a (μM)
HIV-2(ROD)
EC50
a (μM)
HuT-78/HIV-1 + Sup T1
EC50
b (μM)
GNAmaize 0.46 ± 0.13 ≥ 0.83 >1.67
GNA 0.007 ± 0.001 0.008 ± 0.001 0.062 ± 0.064
a50% Effective concentration or compound concentration required to inhibit
virus-induced cytopathicity in CEM cell cultures by 50%.
b50% Effective concentration or compound concentration required to inhibit
syncytia formation between HuT-78/HIV-1 and Sup-T1 cells by 50%.
Data are means of at least two to four independent experiments.
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and the apparent affinity constant KD (ratio kd/ka)
(Table 5; Figure 3). A ~100-fold difference in KD-value
was detected between both plant lectins when evaluated
against HIV-1 gp120 (CHO cell-derived). The apparent
affinity of GNA for gp120 was KD = 0.33 nM, whereas
that of GNAmaize was KD = 34 nM. The kon-values dif-
fered by a factor of ~ 20 and the koff-values by ~ 5-fold.
GNA has a two-fold better affinity and GNAmaize a 2-
fold weaker affinity for HIV-1 gp120 (insect cell-derived)
compared to HIV-1 gp120 (CHO cell-derived).
Affinity analysis for the interactions of various
oligosaccharides with GNAmaize and GNA
To verify the nature of the sugar specificity of GNAmaize
and GNA for gp120 binding, different glycan structures
were evaluated for their binding capacity to immobilized
GNAmaize and GNA (Figure 4). Serial two-fold dilutions
of (a1,2-man)3 [7.8-1000 μM], (a1,3-man)2 [62.5-2000
μM], (b1,4-GlcNAc)3 [7.8-1000 μM] and GlcNAcß1,2-
Man [250-1000 μM] were injected as analyte over
immobilized GNAmaize and GNA. The apparent KD was
calculated by steady-state affinity analysis (Table 6).
Under these experimental conditions, only GlcNAcß1,2-
Man was able to measurably bind to GNAmaize but at
rather low amplitudes. However, this oligosaccharide
didn’t bind to immobilized GNA. In contrast, (a1,2-
man)3 and (a1,3-man)2 efficiently interacted with GNA
at apparent affinity values (KD) of 1.50 mM and 4.44
mM, respectively, but did not bind to GNAmaize. These
findings confirm the striking glycan specificity shift of
GNAmaize when compared to GNA.
Competition of GNA, GNAmaize and mAb 2G12 for binding
to HIV-1 gp120
To investigate whether GNA, GNAmaize and 2G12 mAb
compete for binding to immobilized gp120, the follow-
ing experiment was performed (Figure 5). 20 μM GNA-
maize (green and magenta curves) or 5 μM GNA (red
and blue curves) were administered for 2 minutes to
Figure 1 Antiviral activity of GNA (black triangle) and GNAmaize (black circle) in cell culture. Inhibitory activity against HIV-1(IIIB) (Panel A)
and HIV-2(ROD) (Panel B), respectively, in CEM cell cultures. Panel C: Inhibitory activity against HIV-1(IIIB) in cocultivation of HuT78/HIV-1 with
SupT1. Panels D and E: Inhibitory activity against DC-SIGN-mediated capture of HIV-1(IIIB) by Raji/DC-SIGN (Panel D) and subsequent virus
transmission to CD4+ T-cells (Panel E).
Table 2 Antiviral activity of GNAmaize and GNA in PBMC
against clinical isolates
CBA EC50
a (μM)
Clade A,
UG273
Clade B,
BaL
Clade C,
DJ259
Clade A/E,
ID12
GNAmaize 1.4 >1.6 >1.6 >1.6
GNA 0.046 0.13 0.84 0.38
a50% Effective concentration or compound concentration required to inhibit
p24 production of HIV-infected PBMC.
Table 3 Inhibitory activity of GNAmaize and GNA on DC-
SIGN-mediated capture of HIV-1(IIIB) by DC-SIGN
+ cells
and subsequent virus transmission to CD4+ T cells
CBA EC50
a (μM)
Capture Transmission
GNAmaize 0.90 ± 0.40 0.44 ± 0.09
GNA 0.04 ± 0.01 0.006 ± 0.005
a50% Effective concentration required to inhibit HIV-1 capture by DC-SIGN
and subsequent transmission to CD4
+ T-cells.
Hoorelbeke et al. Retrovirology 2011, 8:10
http://www.retrovirology.com/content/8/1/10
Page 6 of 16
gp120 immobilized on the sensor chip (Figure 5A, con-
dition 1). Immediately at the end of the association
phase (at 120 sec) 20 μM GNAmaize was injected again
as such (green curve) or in the presence of 5 μM GNA
(magenta curve) for another 120 sec (Figure 5A, condi-
tion 2). After this time period, the dissociation phase
was started (Figure 5A, condition 3). Likewise, in the
GNA-binding experiment (red/blue curves), 5 μM GNA
that was injected at condition 1, was injected after 120
sec again as such (red curve) or in the presence of 20
μM GNAmaize (blue curve) for another 120 sec (Figure
5A, condition 2). Whereas the amplitude (RU) markedly
further increased upon addition of 5 μM GNA to 20 μM
GNAmaize (~ 76% from the amplitude recorded when 5
μM GNA was injected as such), addition of 20 μM GNA-
maize to 5 μM GNA hardly further increased the ampli-
tude afforded by GNA as such. These findings may
indicate that GNAmaize pre-binding to gp120 does not
prevent additional GNA binding very much; however,
GNA pre-binding seems to markedly preclude additional
GNAmaize binding. In panel B, a similar experiment was
performed, but now it was the aim to evaluate whether
the plant lectins compete with 2G12 for binding to
immobilized gp120. In condition 1 of Figure 5B GNA-
maize (20 μM) (green and magenta curves) and GNA (5
μM) (blue and red curves) were injected and sustained
for 120 sec till at the start of condition 2 when additional
2G12 (3 μM) (competing with GNAmaize or GNA for
binding to gp120) has been administered to the analyte
(magenta and blue curves). Control curves where the
initial compound injection is sustained without additional
injection of another compound are green (GNAmaize) and
red (GNA). The data revealed that 2G12 could efficiently
(~ 90%) bind to gp120 that contained pre-bound GNA-
maize (Figure 5B, magenta curve, condition 2) but not very
efficiently (~ 20%) bind to gp120 that contained pre-
bound GNA (Figure 5B, blue curve, condition 2). In
panel C, 3 μM 2G12 was injected for 120 seconds (red
curve) (condition 1). This concentration of 2G12 was
kept in condition 2 of Figure 5C, but at that time point
also 5 μM GNA (green curve), 20 μM GNAmaize (blue
curve) or no additional injection were administered (red
curve). It was found that when 3 μM 2G12 were bound
to gp120, ~ 70% of 5 μM GNA or ~ 85% of 20 μM GNA-
maize can still bind to gp120.
Competition between PHA-E or SNA and GNA, GNAmaize
or mAb 2G12 for binding to HIV-1 gp120
A similar competition experiment was performed as
described above, but 2.5 μM PHA-E (Figure 6A) or 2.5
μM SNA (Figure 6B) were injected at time point 1 and
sustained at time point 2 at which additionally 15 μM
GNAmaize (blue), 2.5 μM 2G12 (red) or 0.25 μM GNA
(green) were injected. The lectin PHA-E is known to
preferentially bind to complex-type N-glycans through
the recognition of Galb1,4GlcNAc- and GlcNAcb1,2-
Man-determinants [29]. SNA binds preferentially to sia-
lic acid attached to galactose in a2,6- and to a lesser
Figure 2 Selection of GNAmaize resistance development in HIV-1(IIIB)-infected CEM cell cultures. Arrows indicate the time points where
virus isolates were taken for further characterisation. GNAmaize_1, GNAmaize_2 and GNAmaize_3 represent three independent subcultivation
schedules.
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Table 4 Amino acid mutations that appeared in the envelope of HIV-1(IIIB) strains under sustained GNAmaize or GNA
pressure
putative
glycosylation motifs
in HIV-1(IIIB) gp160
type of
N-
glycan
GNAmaize_1#8 GNAmaize_1#19 GNAmaize_2#14 GNAmaize_3#16 GNAmaize_3#19 GNAmaize_3#27 GNA
c
S29[N,S]b
A48T
K59[K,E]
A70T
88NVT90 complex T90[T/
I]
V101[I,V] V101[I,V]
H105[N,H]
136NDT138 complex
141NSS143 complex
156NCS158 complex
160NIS162 complex
F175L
186NDT188 complex
197NTS199 complex
230NKT232 high
mannose
T232M
234NGT236 high
mannose
N234K
241NVS243 high
mannose
262NGS264 high
mannose
E268K
276NFT278 complex
289NQS291 high
mannose
N289
[N,D]
S291
[S,F]
295NCT297 high
mannose
301NNT303 complex [N,Y]301Y [N,Y]301Y [N,Y]301Y [N,Y]301Y [N,Y]301Y [N,Y]
301Y
A329[T,A]
332NIS334 high
mannose
339NNT341 high
mannose
T341I
356NKT358 complex
G379[E,G]
386NST388 high
mannose
392NST394 high
mannose
T394I
397NST399 complex
401NNT403 complex
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extent a2,3-linkage [30]. The data revealed that 0.25 μM
GNA (green) and 2.5 μM 2G12 (red) can independently
bind on PHA-E pre-bound gp120, whereas GNAmaize
(blue) could not bind any more to PHA-E pre-bound
gp120 (Figure 6A). Likewise, the mAb 2G12 (red) and
GNA (green) could rather efficiently bind to SNA pre-
bound gp120 in contrast to GNAmaize that only could
partially bind to SNA pre-bound gp120 (Figure 6B).
Control injections of 15 μM GNAmaize (blue), 0.25 μM
GNA (green) and 2.5 μM mAb 2G12 (red) are shown in
Figure 6C.
Homology modeling of GNAmaize
Docking experiments performed with MeMan as a
ligand suggested that GNAmaize readily differs from
GNA by the number of active carbohydrate-binding
sites (Figure 7, Panels A and B). The GNA protomer
possesses 3 active MeMan-binding sites which contain
the conserved Gln-X-Asp-X-Asn-X-Val-X-Tyr monosac-
charide-binding sequence (Figure 7, Panel B).
Differences in the key residues that create a network of
hydrogen bonds responsible for the binding of MeMan
to site I of GNA rendered this binding site in GNAmaize
completely inactive. Except for a Val residue, which is
replaced by a Cys residue in GNAmaize, site II is appar-
ently fully active; however the His78 of GNAmaize
(which replaces Ala in GNA) creates a steric clash with
O6 of MeMan and prevents the monosaccharide to be
correctly bound to the site (Figure 7, Panel D,E and F).
Compared to site II of GNA (Figure 7, Panel G,H and I),
site II of GNAmaize should be devoid of any binding activ-
ity toward MeMan and Man. Finally, site III of GNAmaize,
which contains the unchanged key residues Gln95,
Asp97, Asn99, Val101 and Tyr103 as in GNA, does not
differ from site III of GNA (Figure 7, Panel M,N and O),
and thus appears as the only active MeMan/Man-binding
site in the GNAmaize protomer (Figure 7, Panel J,K and
L). These docking results fully support the reduced activ-
ity of GNAmaize towards Man and high-mannose type
glycans compared to GNA. In addition, the shape and
Table 4 Amino acid mutations that appeared in the envelope of HIV-1(IIIB) strains under sustained GNAmaize or GNA
pressure (Continued)
G404R
G410[E,G]
A433[T,A] A433[T,A]
A436[T,A]
448NIT450 high
mannose
G458[S,G]
463NGS465 complex
G471[E,G]
606NAS608 N.D.a
611NKS613 N.D.
620NMT622 N.D.
632NYT634 N.D.
669NIT671 N.D.
745NGS747 N.D.
811NAT813 N.D. T813[T,I]
aNo assignment of the nature of the glycans was found back in the literature.
bThis amino acid change results in the creation of a new putative N-glycosylation site (italics).
Assignment of high mannose- or complex type glycans according to Leonard et al. [28]. Amino acid sequence numbering according to Kwong et al. [47].
Mutated amino acids in bold result in the deletion of a glycosylation motif.
c Data taken from Balzarini et al. [35].
d This glycosylation motif is present in HIV-1(NL4.3), but not in HIV-1(IIIB).
Table 5 Kinetic data for the interaction of GNA and GNAmaize with immobilized HIV-1 IIIB gp120
KD (nM) ka (1/Ms) kd (1/s)
GNA vs IIIB gp120 (CHO) 0.33 ± 0.07 (2.81 ± 0.68) E+06 (9.00 ± 1.14) E-04
GNA vs IIIB gp120 (Baculovirus) 0.17 ± 0.12 (2.75 ± 1.56) E+06 (3.63 ± 0.75) E-04
GNAmaize vs IIIB gp120 (CHO) 34 ± 13 (1.37 ± 0.78) E+05 (5.24 ± 4.50) E-03
GNAmaize vs IIIB gp120 (Baculovirus) 77 ± 17 (2.23 ± 0.74) E+04 (1.64 ± 0.20) E-03
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size of the carbohydrate-binding cavities corresponding
to sites II and III also differ between GNAmaize and GNA
(Figure 7, Panel D,G,J and M), which could account for
the specificity of GNAmaize towards complex glycans.
Moreover, even though site I of GNAmaize does not con-
tain all the residues required for a proper binding of
Man, this region possesses a deep electronegatively
charged cavity (Figure 7, Panel C) that could serve as a
monosaccharide-binding site for simple sugars different
from Man, e.g. for GlcNAc.
Discussion
Our antiviral data and previous observations [11]
revealed that GNA and GNAmaize both inhibit HIV-1
and HIV-2 infection. However GNAmaize shows a
strongly reduced anti-HIV-activity compared to GNA,
being ~60- to ~100-fold less potent against HIV-1(IIIB)
and HIV-2(ROD) infection. It was 30-fold inferior to
inhibit giant cell formation between persistently HIV-1-
infected HuT-78 cells and uninfected SupT1 cells, and it
was 20- to 70-fold less efficient in inhibiting DC-SIGN-
directed HIV-1 capture and subsequent transmission of
DC-SIGN-captured HIV-1 particles to uninfected CD4+
T-lymphocytes (Tables 1, 2, 3). The decreased antiviral
activity is in agreement with the much lower affinity [~
100-fold higher apparent affinity constant (KD)] that was
recorded for the interaction between GNAmaize and
gp120 compared to GNA and gp120. This value points
to a ~ 100-fold weaker binding of GNAmaize than GNA
to gp120. Thus, despite the high similarities at the
sequence and structural level, both plant lectins have a
strikingly different potency for their anti-HIV activity
and interaction with their antiviral target (HIV gp120).
Thus, the weaker contribution to the inhibitory effect
against the HIV-1 infection by GNAmaize is closely cor-
related with its weaker binding to HIV-1 gp120, pre-
sumably due to its carbohydrate specificity shift from
oligomannose (for GNA) to complex-type glycans. In
Figure 3 Kinetic analysis of the interactions of GNAmaize (A, C) and GNA (B, D) with immobilized HIV-1 IIIB gp120 isolated from CHO
cell cultures and from Baculovirus using SPR technology. Serial two-fold analyte dilutions (covering a concentration range from 5 to 80 nM
and from 39 to 625 nM, respectively) were injected over the surface of the immobilized gp120. The experimental data (coloured curves) were fit
using the 1:1 binding model (black lines) to determine the kinetic parameters. The data are a representative example of three independent
experiments. The biosensor chip density was 822 RU for gp120 from CHO (or 6.9 fmol gp120) (panels A & B) and 725 RU for gp120 from
Baculovirus (or 6.0 fmol gp120) (panels C & D).
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this respect, it cannot be excluded that the anti-HIV
activity of GNAmaize may be due, not only to a binding
to complex-type glycans present on HIV-1 gp120 but
also to potential binding to complex-type glycans of
gangliosides that may be present in the virion envelope.
In the long-term drug selection experiments with
GNAmaize, one N-glycan deletion in gp120 (N301) was
observed when all virus strains were taken into account
(Table 4). The deletion represents a complex-type gly-
can deletion [28]. This N-linked sugar chain is the only
one present in the V3-loop of the HIV-1 envelope. This
complex-type N-glycan is conserved in most HIV-1
strains. The N301 glycan is in close proximity to impor-
tant protein domains, in contrast to the complex glycans
at V1/V2 or V4 of gp120. The V3 loop has been impli-
cated in the binding of gp120 with CD4 and the chemo-
kine secondary receptors [31]. It also plays a role in
eliciting neutralizing anti-HIV antibodies [32,33]. Inter-
estingly, the glycan present at N301 was earlier deter-
mined to be occupied by a tetraantennary complex
glycan while most other complex type N-glycans are
predominantly diantennary [34]. This finding may raise
the possibility that a multivalent interaction with more
than two antennae is favourable for GNAmaize binding,
although a glycan array revealed that GNAmaize showed
the highest binding affinities to biantennary (or mono-
antennary) GlcNAc b1-2Man-containing glycans [11]. In
contrast, HIV-1 exposure to GNA resulted in the even-
tual deletion of 7 glycosylation sites of which 5 were
high-mannose-type N-glycans (N230, N234, N289, N339
and N392) and only 2 complex-type N-glycans (N88
and N301) [35]. Similar preference for the deletion of
high-mannose-type glycans has also been observed for
the Hippeastrum hybrid (Amaryllis) lectin HHA [36],
the prokaryotic lectin actinohivin [37,38], the cyanobac-
terial lectin Cyanovirin N [39], the 2G12 mAb [40] and
the antibiotics pradimicin A and S [41,42]. Such unusual
preference for deletion of high-mannose-type glycans is
highly significant for these lectins since the glycan shield
of the HIV-1 gp120 envelope, determined for gp120
expressed in Chinese hamster ovary (CHO) cells, exists
of 11 high-mannose- or hybrid-type glycans and 13
complex-type glycans [28]. It was interesting to notice
that one of the GNAmaize-exposed virus strains also
Figure 4 Affinity analysis of (a1,2-man)3, (a1,3-man)2, (b1,4-GlcNAc)3 and GlcNAcß1,2Man with immobilized GNAmaize and GNA. Serial
two-fold analyte dilutions were injected over the surface of the GNAmaize- (Panels A to D)- or GNA- (Panels E to H)-bound sensor chip. These
dilutions covered a concentration range from 7.8 to 1000 μM for (a1,2-man)3, and (b1,4-GlcNAc)3 (Panels A, C, E, G), 62.5 to 2000 μM for (a1,3-
man)2, (Panels B, F) and 250 to 1000 μM for GlcNAcß1,2Man (Panels D, H). The apparent KD was calculated by steady-state affinity analysis. The
curves represent a representative example of two independent experiments. The biosensor chip density was 7230 RU for GNAmaize (or 120 fmol
GNAmaize) and 2455 RU for GNA (or 49 fmol GNA).
Table 6 Affinity data for the interactions of various
oligosaccharides with immobilized GNA and GNAmaize
Glycan KD
GNA GNAmaize
(a1,2-man)3 1.5 ± 0.2
mM
N.D.a
(a1,3-man)2 4.4 ± 0.9
mM
N.D.
(ß1,4-GlcNAc)3 N.D. N.D.
GlcNAcb1,2Man N.D. binding
detectedb
GlcNAcb1,2Mana1,3(GlcNAcb1,2Mana1,6)
Manb1,4GlcNAcb1,4GlcNAc
N.D. binding
detectedb
aNot detectable. For these interactions no binding curves could be detected.
bBinding was observed but we were unable to determine the KD-value.
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showed a glycosylation site deletion in gp41. It should,
however, be kept in mind that the N811 position is
located in the cytoplasmic tail of gp41 and thus was not
supposed to be glycosylated in wild-type gp41. The rele-
vance of the appearance of this mutation is therefore
unclear. Also, the relevance of the formation of the new
glycosylation motif at N29 in gp120 of one of the virus
isolates is unclear because this amino acid is located in
the membrane-embedded signal peptide and thus unli-
kely to be used for glycosylation.
Fouquaert and colleagues [11] demonstrated by glycan
array analysis that GNA strongly interacts with high-man-
nose-type N-glycans and preferentially recognizes terminal
mannose residues (Mana1,6Man > Mana1,3Man >
Mana1,2Man), whereas GNAmaize has poor, if any affinity
for this type of glycans. In contrast, GNAmaize recognizes
complex N-glycans with a preference for a GlcNAc
b1,2Mana1,3-X motif-containing glycan and/or a Neu5A-
ca2,6Galb1,4-X motif-containing glycan. Thus, this sur-
prising shift in glycan specificity from high-mannose-type
to complex-type glycans between the closely related GNA
and GNAmaize explains the differences between both lec-
tins in their preference for the nature (high mannose-type
for GNA and complex-type for GNAmaize) of the deletion
of N-glycans in the drug resistance selection experiments.
To further document this shift in sugar recognition we
performed several surface plasmon resonance (SPR)
experiments. In the first instance 5 oligosaccharides:
(a1,2-man)3, (a1,3-man)2, (b1,4-GlcNAc)3, GlcNAcß1,2-
Man and GlcNAcb1,2Mana1,3(GlcNAcb1,2Mana1,6)
Figure 5 Panel A: Competition experiment between GNAmaize and GNA for binding to HIV-1 IIIB gp120 (chip density 400 RU ~ 3.3
fmol). 20 μM GNAmaize were injected (time point 1, green and magenta), followed after 2 minutes by injection of 20 μM GNAmaize (time point 2)
in the absence (green) and presence of 5 μM GNA (magenta). Also 5 μM GNA (time point 1, red and blue) were injected followed by injection
of 5 μM GNA (time point 2) in the absence (red) and presence of 20 μM GNAmaize (blue). In Panel B, the competition experiment was performed
between the plant lectins GNA and GNAmaize, and the mAb 2G12 for binding to immobilized IIIB gp120. 20 μM GNAmaize (green and magenta)
and 5 μM GNA (red and blue) were injected as such (first 120 sec), followed by an additional injection of 3 μM 2G12 (next 120 sec) (in the
continued presence of GNAmaize [magenta] or GNA[blue]). In Panel C, 3 μM of 2G12 were injected (time point 1, red, blue and green) followed
after 120 sec by an additional injection of 20 μM GNAmaize (blue), 5 μM GNA (green) or by no injection (red) (time point 2) for another 120
seconds, in the continued presence of 3 μM 2G12.
Figure 6 Competition experiment between PHA-E (Panel A) or SNA (Panel B) with GNAmaize (blue), GNA (green) or mAb 2G12 (red) for
binding to HIV-1 gp120. In Panel A, 2.5 μM of PHA-E were injected at time point 1, this concentration of PHA-E was sustained at time point 2
but now also 15 μM GNAmaize (blue), 2.5 μM 2G12 (red) or 0.25 μM GNA (green) were additionally injected. A similar experiment was performed
for 2.5 μM SNA (B). Control injections of 15 μM GNAmaize (blue), 0.25 μM GNA (green) and 2.5 μM mAb 2G12 (red) are plotted in panel C.
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Figure 7 Panel A and B: ribbon diagrams of GNAmaize (A) and GNA (B) highlighting the mannose-binding sites I, II and III in both
structures. Panel C: electronegative cavity (white dotted line) in the region of site I of GNAmaize (open white circle in Panel A) containing
residues Ser24, Glu26, Ala26, Tyr38, Asn40 and Asn41 that could be involved in the binding of monosaccharides. Electronegative and
electropositive potentials are colored red and blue, respectively. Neutral regions are colored white. Panel D,G,J and M: topography of site II of
GNAmaize (D) and GNA (G) and site III of GNAmaize (J) and GNA (M) showing the anchoring of MeMan into the mannose-binding cavity. The
yellow star indicates the protruding His78 residue that creates a steric clash with O6 of MeMan (D). The overall topography of the mannose-
binding sites is indicated by red dotted lines. Panel E,H,K and N: ribbon diagrams showing the anchoring of MeMan into mannose-binding site II
of GNAmaize (E) and GNA (H) and site III of GNAmaize (K) and GNA (N). Residues interacting with MeMan are in stick representation and are
labelled. Panel F,I,L and O: stick representation of residues interacting with MeMan in site II of GNAmaize (F) and GNA (I) and site III of GNAmaize
(L) and GNA (O). Hydrogen bonds are represented by deep blue dotted lines. Note the steric clash occurring between His78 and O6 of MeMan
in site II of GNAmaize (F).
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Manb1,4GlcNAcb1,4GlcNAc were examined for binding
to immobilized GNA and GNAmaize. The SPR-results
showed that only (a1,2-man)3 and (a1,3-man)2 preferen-
tially bind to GNA but not GNAmaize whereas
GlcNAcß1,2Man and GlcNAcb1,2Mana1,3(GlcNAcb1,2-
Mana1,6) Manb1,4GlcNAcb1,4GlcNAc were able to bind
to GNAmaize but not to GNA. We found a slightly higher
preference of GNA for (a1,2-man)3 than for (a1,3-man)2
whereas GNA was originally reported by Shibuya and co-
workers [12] as a lectin with specificity towards oligosac-
charides with terminal Mana1,3Man motifs. However, it
should be noticed that in our SPR studies, a a1,3-man
dimer but a a1,2-man trimer has been used. It is well
known that often a higher degree of oligomerization
results in a better affinity of the lectins for such sugar oli-
gomers. The concomitant a1,2-man specificity of GNA is
also in line with the glycan array data of Fouquaert et al.
[11], and the a1,2-mannose oligomer affinity of GNA
became also evident from the 2-fold lower KD-value of
GNA binding to insect cell-derived gp120 (containing a
high density of high-mannose-type glycan structures) than
CHO cell-derived gp120 (Table 5). The 2-fold weaker affi-
nity of GNAmaize against insect cell-derived gp120 com-
pared to CHO-derived HIV-1 gp120 is also in line with its
predominant complex-type glycan specificity.
Epitope mapping experiments beween PHA-E (that
prefers Galb1,4GlcNAc- and GlcNAcb1,2Man-linkages)
or SNA (with Neu5Aca2,6Gal- and Neu5Aca2,3Gal-
specificity) and GNA or GNAmaize for binding to gp120
revealed that PHA-E pre-binding to gp120 prevents
additional binding of GNAmaize, in contrast to GNA,
and SNA pre-binding of gp120 partially prevents the
binding of GNAmaize on gp120 but does not influence
the additional binding of GNA to gp120. Taking into
account the lectin-gp120 affinity data (Table 6) it can be
concluded that the GNAmaize lectin preferentially binds
to GlcNAcb1,2Mana1,3-X motifs and to a lesser, but
still significant degree also to Neu5Aca2,6Galb1-X
motif determinants present on HIV-1 gp120. These data
are in agreement with the findings of Fouquaert et al.
[11] who demonstrated by glycan array analysis that
GNAmaize appears to prefer complex-type glycans con-
taining GlcNAcb1,2Man motifs and interactions with
glycans containing Neu5Aca2,6Gal residues. When
competition experiments between GNA, GNAmaize and
2G12 for binding to gp120 were performed using SPR-
analysis, GNA and GNAmaize virtually bound indepen-
dently of each other to gp120, although the amplitude
of GNA decreased somewhat by 24% when gp120 was
saturated with GNAmaize (Table 7). Similar phenomena
were observed with the a1,2-mannose specific anti-
gp120 mAb 2G12 [43] binding of gp120: the binding
signals of the snowdrop GNA lectin and the GNAmaize
lectin are diminished by 30% and 15% against 2G12 pre-
bound gp120, respectively. These data prove that GNA
has a more pronounced specificity for a1,2-man (com-
peting for binding to the 2G12 epitope), in contrast to
GNAmaize which has rather weak, if any affinity (specifi-
city) for a1,2-mannose oligomers.
The Mana1,2-man oligomer-specific lectins [i.e. cya-
novirin-N [39], Pradimicin A [41], Pradimicin S [42],
actinohivin [38] and the mAb 2G12 [40]] and mana1,3/
a1,6-man-oligomer specific lectins (i.e. GNA and HHA
[8]) have previously been reported to contain potent
anti-HIV activity. This mana1,2-, a1,3 or a1,6-man oli-
gomer preference of GNA disappeared almost comple-
tely for the structurally closely related GNAmaize and,
likewise, resulted in a seriously decreased antiviral activ-
ity and a markedly lower affinity for HIV-1 gp120.
These findings reveal the importance of interaction of
CBAs with high-mannose-type glycans (preferentially
mana1,2man) on the HIV gp120 envelope protein as a
prerequisite to exhibit pronounced antiviral activity.
Although the designation of complex versus high-man-
nose-type glycans on gp120 is based on the study of
Leonard et al. [28] using monomeric recombinantly
expressed gp120, it is well possible that the glycan con-
tent of the native gp120 trimer on the viral particles is
somewhat different. In fact, Doores et al. [44] recently
revealed that the envelope of native HIV virions, in
sharp contrast to recombinantly gp120, almost exclu-
sively contains an oligomannose (Man5-9GlcNAc2) gly-
can profile (< 2% complex-type glycans). However, it
should be kept in mind that a proportion of the high-
mannose-type glycans determined on virion trimeric
gp120 can be derived from non-functional envelope
forms of the virus containing a different glycosylation
profile and therefore the amount of high-mannose-type
glycans on the gp120 of virus particles can somewhat be
overestimated in this study.
In conclusion, the markedly reduced effect in anti-HIV
activity (up to ~100-fold) of GNAmaize compared to GNA
is explained by the shift in glycan recognition from high-
mannose to complex-type glycans, and underscores the
importance of efficient mannose-oligomer recognition of
therapeutics as a prerequisite to exert significant anti-
HIV activity. These findings would justify a rational
design of new carbohydrate-binding therapeutics selec-
tively targeting the high-mannose type glycans present
on the HIV envelope gp120. Therefore, a better under-
standing of the molecular interaction between mannose-
binding lectins such as actinohivin, cyanovirin, microvirin
or griffithsin with a1,2-mannose oligomers by NMR or
crystallography interaction studies would allow rational
design of small synthetic carbohydrate (mannose)-bind-
ing agents. Also, (small-size) synthetic compounds such
as borane-containing compound derivatives, known to
specifically recognize configurations of two hydroxyl
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groups in cis (such as being present in mannose) [45,46]
should be explored for gp120 binding and anti-HIV
activity.
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